Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines

Genes Chromosomes and Cancer

Volumn 44, Issue 1, 2005, Pages 37-51

  Gysin, Stephan ^a   Rickert, Paula ^b   Kastury, Kumar ^b   McMahon, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CDKN2A GENE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DETERMINATION; DNA MICROARRAY; DPC4 GENE; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; KRAS2 GENE; METASTASIS; ONCOGENE; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TP53 GENE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; DNA, NEOPLASM; GENE AMPLIFICATION; HUMANS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 23044515381     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20216     Document Type: Article

References (71)

1. Aguirre AJ, Burdeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112-3126.
2. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N and others. 2004. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 101:9067-9072.
3. Albertson DG, Collins C, McCormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nat Genet 34:369-376.
4. Albertson DG, Pinkel D. 2003. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 12:R145-R152.
5. Armengol G, Knuutila S, Lluis F, Capella G, Miro R, Caballin MR. 2000. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet 116:133-141.
6. Bardeesy N, DePinho RA. 2002. Pancreatic cancer biology and genetics. Nat Rev Cancer 2:897-909.
7. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz, CM. 2001. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61:8068-8073.
8. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. 1999. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1:50-62.
9. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE. 2003. BRAF and FBXW7 (CDC4, FBW7, AGO. SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 163:1255-1260.
10. Clark EA, Golub TR, Lander ES, Hynes RO. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535.
11. Cross MJ, Dixelins J, Matsumoto T, Claesson-Welsh L. 2003. VEGF-receptor signal transduction. Trends Biochem Sci 28:488-494.
12. Dahiya R, Kwak KS, Byrd JC, Ho S, Yoon WH, Kim YS. 1993. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res 53:1457-1443.
13. Drucker BJ, Marincola FM, Siao DY, Donlon TA, Bangs CD, Holder WD Jr. 1988. A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev Biol 24: 1179-1187.
14. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM. 2001. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61:4222-4228.
15. Fidler IJ. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458.
16. Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A. 1997. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19:161-169.
17. Geradts J, Hruban RH, Schutte M, Kern SE, Maynard R. 2000. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTSI gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 8:71-79.
18. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR. 1989. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 45:1037-1041.
19. Guo W, Giancotti FG. 2004. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816-826.
20. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
21. Heidenblad M, Jonson T, Mahlamaki EH, Gorunova L, Karhu R, Johansson B, Hoglund M. 2002. Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. Genes Chromosomes Cancer 34:211-23.
22. Heidenblad M, Schoenmakers EF, Jonson T, Gorunova L, Veltman JA, van Kessel AG, Hoglund M. 2004. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 64:3052-3059.
23. Heighway J, Betticher DC, Hoban PR, Altermatt HJ, Cowen R. 1996. Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG. Genomics 35:207-214.
24. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-450.
25. Holzmann K, Kohlhammer H, Schwaenen C, Wessendorf S, Kestler HA, Schwoerer A, Rau B, Radlwimmer B, Dohner H, Lichter P, Gress T, Bentz M. 2004. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res 64:4428-4433.
26. Hruban RH, Goggins M, Parsons J, Kern SE. 2000. Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972.
27. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. 2001. Molecular pathology of pancreatic cancer. Cancer J 7:251-258.
28. Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, Kuroki T, Trapasso F, Nishimura M, Saito Y, Ozawa K, Croce CM, Huebner K, Furukawa Y. 2003. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1:940-947.
29. Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, Griffin CA. 1998. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 4:194-203.
30. Jaffee EM, Hruban RH, Canto M, Kern SE. 2002. Focus on pancreas cancer. Cancer Cell 2:25-28.
31. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. 2002. Fully automatic quantification of microarray image data. Genome Res 12:325-332.
32. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmuller G. 1993. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298.
33. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. 2001. A while paper: the product of a pancreas cancer think tank. Cancer Res 61:4923-4932.
34. Kern SE, Hruban RH, Hidalgo M, Yeo CJ. 2002. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 1:607-613.
35. Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, Rattan S, Cesari R, Nolli ML, Williams NN, Mori M, Kanematsu T, Croce CM. 2004. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10:2459-2465.
36. Kyriazis AP, McCombs WB, 3rd, Sandberg AA, Kyriazis AA, Sloane NH, Lepera R. 1983. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res 43:4393-4401.
37. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. 1975. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15:741-747.
38. Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM. 2003. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100(1-4):101-110.
39. Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, Andren-Sandberg A, Kallioniemi OP, Johansson B. 1997. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer 20:383-391.
40. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M. Karhu R, Kallioniemi A. 2002. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35:353-358.
41. Mahlamaki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. 2004. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 6:432-439.
42. Metzgar RS, Gaillard MT, Levine SJ, Tuck FL, Bossen EH, Borowitz MJ. 1982. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res 42: 601-608.
43. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M, Scarpa A. 2001. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439:798-802.
44. Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T, Kanematsu T. 1993. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg 217:138-143.
45. Nagy A, Kozma L, Kiss I, Ember I, Takacs I, Hajdu J, Farid NR. 2003. Copy number of cancer genes predict tumor grade and survival of pancreatic cancer patients. Anticancer Res 21:1321-1325.
46. Norman J, Franz M, Schiro R, Nicosia S, Docs J, Fabri PJ, Gower WR Jr. 1994. Functional glucocorticoid receptor modulates pancreatic carcinoma growth through an autocrine loop. J Surg Res 57:33-38.
47. Owens RB, Smith HS, Nelson-Rees WA, Springer EL. 1976. Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst 56:843-849.
48. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, Porteous DJ, Smyth JF, Gabra H, Watson JEV. 2001. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98:11417-11422.
49. Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC, Aldaz CM. 2004. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 91:753-759.
50. Patlolla JM, Swamy MV, Raju J, Rao CV. 2004. Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep 11:957-963.
51. Peiper M, Nagoshi M, Patel D, Fletcher JA, Goegebuure PS, Eberlein TJ. 1997. Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int J Cancer 71:993-999.
52. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. 2002. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 3:748-754.
53. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. High resolution analysis of DNA copy number variation using comparative gcnomic hybridization to microarrays. Nat Genet 20:207-211.
54. Sato N, Mizumoto K, Beppu K, Maehara N, Kusumoto M, Nabae T, Morisaki T, Katano M, Tanaka M. 2000. Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential. Cancer Lett 155:153-161.
55. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. 2002. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 15:462-469.
56. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. 2003. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100:7737-7742.
57. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677.
58. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. 2003. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442:444-152.
59. Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, Flake GP, Taylor JA. 2000. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1223-1232.
60. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, Albertson DG. 2001. Assembly of microarrays for genomewide measurement of DNA copy number. Nat Genet 29:263-264.
61. Snijders AM, Nowee ME, Fridlyand J, Piek JM, Dorsman JC, Jain AN, Pinkel D, van Diest PJ, Verheijen RH, Albertson DG. 2003. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 22:4281-4286.
62. Snijders AM, Segraves R, Blackwood S, Pinkel D, Albertson DG. 2004. BAC microarray-based comparative genomic hybridization. Methods Mol Biol 256:39-56.
63. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass HO Jr, Chu TM. 1986. Characterization of a new primary human pancreatic tumor line. Cancer Invest 4:15-23.
64. Vezeridis MP, Meitner PA, Tibbetts LM, Doremus CM, Tzanakakis G, Calabresi P. 1990. Heterogeneity of potential for hematogenous metastasis in a human pancreatic carcinoma. J Surg Res 48: 51-55.
65. Vezeridis MP, Tzanakakis GN, Meitner PA, Doremus CM, Tibbetts LM, Calabresi P. 1992. In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse. Cancer 69:2060-2063.
66. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, Kodama T, Aburatani H. 2003. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63:8629-8633.
67. Watson JEV, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, Van Dekken H, Ginzinger D, Haqq C, James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, Simko JP, Volik S, Weinberg VK, Paris PL, Collins C. 2004. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23:3487-3494.
68. Wilentz RE, Chung CH, Sturm PD, Musler A, Sohn TA, Offerhaus GJ, Yeo CJ, Hruban RH, Slebos RJ. 1998a. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 82: 96-103.
69. Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH. 1998b. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58:4740-4744.
70. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon M. 2001. induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 21:3192-3205.
71. Yunis AA, Arimura GK, Russin DJ. 1977. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19:218-235.